Noradrenaline Transporter PET Reflects Neurotoxin-induced Noradrenaline Level Decrease in the Rat Hippocampus

Overview

Journal EJNMMI Res

Date 2023 Sep 15

PMID 37713137

Authors

Takayuki Sakai

Saori Hattori

Aya Ogata

Takashi Yamada

Junichiro Abe

Hiroshi Ikenuma

Masanori Ichise

Masaaki Suzuki

Kengo Ito

Takashi Kato

Yasuyuki Kimura

Affiliations

Soon will be listed here.

Abstract

Background: The neuropathological changes of early Alzheimer's disease (AD) include neurodegenerative loss of noradrenaline neurons in the locus coeruleus with decreasing noradrenaline availability in their projection areas such as the hippocampus. This diminishing noradrenaline availability is thought to play an important role pathophysiologically in the development of cognitive impairment in AD, because noradrenaline is not only essential for maintaining cognitive functions such as memory, learning and attention, but also its anti-inflammatory action, where its lack is known to accelerate the progression of AD in the mouse model. Therefore, the availability of in vivo biomarkers of the integrity of noradrenaline neurons may be beneficial for furthering our understanding of the role played by the noradrenaline system in the progressive cognitive dysfunction seen in AD patients. In this study, we investigated if PET imaging of noradrenaline transporters can predict the level of noradrenaline in the brain. Our hypothesis was PET measured noradrenaline transporter densities could predict the level of noradrenaline concentrations in the rat hippocampus after lesioning of noradrenaline neurons in this region.

Results: We chemically lesioned the hippocampus of rats (n = 15) by administering a neurotoxin, DSP-4, in order to selectively damage axonal terminals of noradrenergic neurons. These rats then underwent PET imaging of noradrenaline transporters using [C]MRB ((S,S)-[C]Methylreboxetine). To validate our hypothesis, postmortem studies of brain homogenates of these rats were performed to measure both noradrenaline transporter and noradrenaline concentrations. [C]MRB PET showed decreased noradrenaline transporter densities in a DSP-4 dose-dependent manner in the hippocampus of these rats. In turn, these PET measured noradrenaline transporter densities correlated very well with in vitro measured noradrenaline concentrations as well as in vitro transporter densities.

Conclusions: [C]MRB PET may be used as an in vivo biomarker of noradrenaline concentrations in the hippocampus of the neurodegenerating brain. Further studies appear warranted to extend its applicability to AD studies.

Citing Articles

Evaluation of specific binding of [C]TZ7774 to the receptor-interacting protein kinase 1 (RIPK1) in the brain.

Sakai T, Yamada T, Ikenuma H, Ogata A, Ichise M, Hattori S Am J Nucl Med Mol Imaging. 2024; 14(5):345-350.

PMID: 39583909 PMC: 11578809. DOI: 10.62347/PAZG6300.

References

Lopez-Picon F, Kirjavainen A, Forsback S, Takkinen J, Peters D, Haaparanta-Solin M . characterization of a novel norepinephrine transporter PET tracer [F]NS12137 in adult and immature Sprague-Dawley rats. Theranostics. 2019; 9(1):11-19. PMC: 6332804. DOI: 10.7150/thno.29740. View

MCENTEE W, Crook T . Age-associated memory impairment: a role for catecholamines. Neurology. 1990; 40(3 Pt 1):526-30. DOI: 10.1212/wnl.40.3_part_1.526. View

Logan J, Wang G, Telang F, Fowler J, Alexoff D, Zabroski J . Imaging the norepinephrine transporter in humans with (S,S)-[11C]O-methyl reboxetine and PET: problems and progress. Nucl Med Biol. 2007; 34(6):667-79. DOI: 10.1016/j.nucmedbio.2007.03.013. View

Ichise M, Liow J, Lu J, Takano A, Model K, Toyama H . Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab. 2003; 23(9):1096-112. DOI: 10.1097/01.WCB.0000085441.37552.CA. View

Ross S . Long-term effects of N-2-chlorethyl-N-ethyl-2-bromobenzylamine hydrochloride on noradrenergic neurones in the rat brain and heart. Br J Pharmacol. 1976; 58(4):521-7. PMC: 1667482. DOI: 10.1111/j.1476-5381.1976.tb08619.x. View

Ding Y, Lin K, Garza V, Carter P, Alexoff D, Logan J . Evaluation of a new norepinephrine transporter PET ligand in baboons, both in brain and peripheral organs. Synapse. 2003; 50(4):345-52. DOI: 10.1002/syn.10281. View

Biegon A, Rainbow T . Localization and characterization of [3H]desmethylimipramine binding sites in rat brain by quantitative autoradiography. J Neurosci. 1983; 3(5):1069-76. PMC: 6564518. View

Moriguchi S, Kimura Y, Ichise M, Arakawa R, Takano H, Seki C . PET Quantification of the Norepinephrine Transporter in Human Brain with ()-F-FMeNER-D. J Nucl Med. 2016; 58(7):1140-1145. DOI: 10.2967/jnumed.116.178913. View

Cheetham S, Viggers J, Butler S, Prow M, Heal D . [3H]nisoxetine--a radioligand for noradrenaline reuptake sites: correlation with inhibition of [3H]noradrenaline uptake and effect of DSP-4 lesioning and antidepressant treatments. Neuropharmacology. 1996; 35(1):63-70. DOI: 10.1016/0028-3908(95)00134-4. View

10.

Ross S, Stenfors C . DSP4, a selective neurotoxin for the locus coeruleus noradrenergic system. A review of its mode of action. Neurotox Res. 2014; 27(1):15-30. DOI: 10.1007/s12640-014-9482-z. View

11.

Pizzagalli D, Berretta S, Wooten D, Goer F, Pilobello K, Kumar P . Assessment of Striatal Dopamine Transporter Binding in Individuals With Major Depressive Disorder: In Vivo Positron Emission Tomography and Postmortem Evidence. JAMA Psychiatry. 2019; 76(8):854-861. PMC: 6495358. DOI: 10.1001/jamapsychiatry.2019.0801. View

12.

Koohsari S, Sadabad F, Pittman B, Gallezot J, Carson R, van Dyck C . Relationships of in vivo brain norepinephrine transporter and age, BMI, and gender. Synapse. 2023; 77(5):e22279. PMC: 10416616. DOI: 10.1002/syn.22279. View

13.

Schou M, Halldin C, Sovago J, Pike V, Hall H, Gulyas B . PET evaluation of novel radiofluorinated reboxetine analogs as norepinephrine transporter probes in the monkey brain. Synapse. 2004; 53(2):57-67. DOI: 10.1002/syn.20031. View

14.

Kalinin S, Gavrilyuk V, Polak P, Vasser R, Zhao J, Heneka M . Noradrenaline deficiency in brain increases beta-amyloid plaque burden in an animal model of Alzheimer's disease. Neurobiol Aging. 2006; 28(8):1206-14. DOI: 10.1016/j.neurobiolaging.2006.06.003. View

15.

Selkoe D, Hardy J . The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016; 8(6):595-608. PMC: 4888851. DOI: 10.15252/emmm.201606210. View

16.

Ding Y, Singhal T, Planeta-Wilson B, Gallezot J, Nabulsi N, Labaree D . PET imaging of the effects of age and cocaine on the norepinephrine transporter in the human brain using (S,S)-[(11)C]O-methylreboxetine and HRRT. Synapse. 2009; 64(1):30-8. PMC: 3727644. DOI: 10.1002/syn.20696. View

17.

Gallezot J, Weinzimmer D, Nabulsi N, Lin S, Fowles K, Sandiego C . Evaluation of [(11)C]MRB for assessment of occupancy of norepinephrine transporters: Studies with atomoxetine in non-human primates. Neuroimage. 2010; 56(1):268-79. PMC: 3710586. DOI: 10.1016/j.neuroimage.2010.09.040. View

18.

Mann D, YATES P, Hawkes J . The noradrenergic system in Alzheimer and multi-infarct dementias. J Neurol Neurosurg Psychiatry. 1982; 45(2):113-9. PMC: 1083037. DOI: 10.1136/jnnp.45.2.113. View

19.

Donnan G, Kaczmarczyk S, McKenzie J, Kalnins R, Chilco P, Mendelsohn F . Catecholamine uptake sites in mouse brain: distribution determined by quantitative [3H]mazindol autoradiography. Brain Res. 1989; 504(1):64-71. DOI: 10.1016/0006-8993(89)91598-9. View

20.

Schou M, Halldin C, Sovago J, Pike V, Gulyas B, Mozley P . Specific in vivo binding to the norepinephrine transporter demonstrated with the PET radioligand, (S,S)-[11C]MeNER. Nucl Med Biol. 2003; 30(7):707-14. DOI: 10.1016/s0969-8051(03)00079-9. View